


Estimated Prevalence of Idiopathic Hypersomnia (IH) in the Wisconsin Sleep Cohort (WSC)



University of Wisconsin SCHOOL OF MEDICINE AND PUBLIC HEALTH

Paul E. Peppard¹, David T. Plante¹, Erika W. Hagen¹, Jodi H. Barnet¹, Emmanuel M. Mignot²

¹University of Wisconsin-Madison, School of Medicine and Public Health; ²Stanford University, Stanford Center for Sleep Sciences and Medicine


BACKGROUND	RESULTS	
Idiopathic hypersomnia (IH) is a neurologic condition characterized by chronic excessive daytime sleepiness despite normal sleep duration in which sleepiness is unexplained by other sleep	Idiopathic Hypersomnia ("probable Case Identification Flowchart	
disorders, behaviors, or other identifiable causes.	WSC MSLT Idiopathic	WSC participants with clinical MSLT = 792

Population-based prevalence estimates of IH are unavailable, though a recent analysis* of a US insured population found ~1/10,000 persons (~0.01%) were diagnosed with IH. However, as with many other sleep disorders, the prevalence of IH is likely to be substantially underestimated using only diagnosed cases.

Here we estimate "probable IH" prevalence in the Wisconsin Sleep Cohort (WSC), a nonclinical population-based cohort of middle-to-olderaged adults. A large subset of the WSC has been assessed for many objective and subjective sleep and sleepiness characteristics that allow for the evaluation of "probable IH" – IH established by multiple research tools but generally without specific IH diagnostic assessment by a sleep medicine specialist.

*Acquavella et al., Prevalence of narcolepsy and other sleep disorders and frequency of diagnostic tests from 2013-2016 in insured patients actively seeking care. J Clin Sleep Med. 2020;16(8):1255-1263.

	Sample (N=792)	hypersomnia sub-sample (N=12)
Female gender, N (%)	383 (48%)	7 (58%)
Age, mean (SD)	59 (8) yr.	57 (8) yr.
BMI, mean (SD)	32 (7) kg/m ²	30 (6) kg/m²
ESS Score>10, N (%)	275 (35%)	12 (100%)
Feelings of excessive daytime sleepiness, often-always, N (%)	144 (18%)	7 (58%)
MSLT sleep latency, mean (SD)	12 (5) min.	6 (2) min.
Daily average sleep duration from 1-week diary including naps, mean (SD)	7.9 (1.0) hr.	8.1 (0.9) hr.
AHI category, N (%)		
0-<5 events/hr	308 (39%)	12 (100%)
5-<15 events/hr	224 (28%)	0%
15+ events/hr	260 (33%)	0%
PSG sleep efficiency, mean (SD)	81% (10%)	82% (15%)
PSG sleep latency, mean (SD)	12 (14) min.	4 (2) min.
Sedative use, N (%)	74 (9%)	0%



METHODS

Sample: The WSC was established in the late 1980s from a working non-clinical population and, over the ensuing decades, has been examined for the natural history of sleep behaviors and common sleep disorders from mid-to-later adulthood. A subset of WSC participants (N=792, 48% female, age range=40-78 years), provided sufficient information for the establishment or exclusion of "probable idiopathic hypersomnia."

Data Collection:

- Overnight in-laboratory polysomnography (PSG)
- Clinical Multiple Sleep Latency Tests (MSLT)
- Epworth Sleepiness Scale (ESS)
- One-week sleep diaries
- Questionnaires regarding sleep problems and habits as well as a broad range of medical, health and sociodemographic information.
- Chart review by sleep medicine specialist (D.T.P.)

Classification of probable idiopathic

hypersomnia: See the "Idiopathic Hypersomnia ("probable IH") Case Identification Flowchart" in Results for a depiction of the process by which probable IH cases were identified.

Antidepressant use, 186 (23 N (%)

Thus, prevalence of "probable IH" in the WSC = ¹²/₇₉₂ = **1.5%** (95%CI=0.7% to 2.4%)

CONCLUSION

Idiopathic hypersomnia (IH) is likely underdiagnosed, perhaps greatly so. We found a prevalence of probable IH approximately 100-fold higher than has been estimated using diagnosed cases. However, there are reasons why our findings may either somewhat overestimate (e.g., missed alternative causes of sleepiness that might be identified in diagnostic interviews) or underestimate (e.g., exclusion of IH due to the presence of OSA that might be masking underlying IH) "true" idiopathic hypersomnia prevalence.

This work was supported by the National Heart, Lung, and Blood Institute (NHLBI, R01HL62252), National Institute on Aging (NIA, R01AG058680) and the National Center for Research Resources (NCRR, 1UL1RR025011) at the US National Institutes of Health, as well as research funding from Jazz Pharmaceuticals.

Contact

Paul E. Peppard, PhD

Dept. of Population Health Sciences, University of Wisconsin-Madison ppeppard@wisc.edu